• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks Whale Activity In Today's Session

    5/31/24 1:35:21 PM ET
    $ABBV
    $BMY
    $CVS
    $DHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    PRAX PUT TRADE BULLISH 07/19/24 $45.00 $37.5K 1.2K 492
    MRNA PUT TRADE BULLISH 06/21/24 $130.00 $27.1K 3.0K 349
    EXEL CALL TRADE BEARISH 11/15/24 $18.00 $75.0K 0 300
    DHR PUT TRADE BULLISH 01/16/26 $260.00 $787.5K 10 300
    BMY PUT TRADE BULLISH 09/20/24 $47.00 $42.8K 3.0K 211
    UNH CALL TRADE BULLISH 07/19/24 $530.00 $66.6K 786 161
    DXCM PUT SWEEP BEARISH 11/15/24 $110.00 $92.7K 346 141
    SRPT CALL SWEEP BEARISH 06/21/24 $160.00 $46.4K 1.0K 117
    ABBV CALL SWEEP BEARISH 06/20/25 $180.00 $89.1K 533 6
    CVS CALL SWEEP BULLISH 01/16/26 $67.50 $27.4K 311 0

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • For PRAX (NASDAQ:PRAX), we notice a put option trade that happens to be bullish, expiring in 49 day(s) on July 19, 2024. This event was a transfer of 50 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $37.5K, with a price of $750.0 per contract. There were 1208 open contracts at this strike prior to today, and today 492 contract(s) were bought and sold.

    • For MRNA (NASDAQ:MRNA), we notice a put option trade that happens to be bullish, expiring in 21 day(s) on June 21, 2024. This event was a transfer of 100 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $27.1K, with a price of $271.0 per contract. There were 3017 open contracts at this strike prior to today, and today 349 contract(s) were bought and sold.

    • For EXEL (NASDAQ:EXEL), we notice a call option trade that happens to be bearish, expiring in 168 day(s) on November 15, 2024. This event was a transfer of 150 contract(s) at a $18.00 strike. The total cost received by the writing party (or parties) was $75.0K, with a price of $500.0 per contract. There were 0 open contracts at this strike prior to today, and today 300 contract(s) were bought and sold.

    • Regarding DHR (NYSE:DHR), we observe a put option trade with bullish sentiment. It expires in 595 day(s) on January 16, 2026. Parties traded 300 contract(s) at a $260.00 strike. The total cost received by the writing party (or parties) was $787.5K, with a price of $2625.0 per contract. There were 10 open contracts at this strike prior to today, and today 300 contract(s) were bought and sold.

    • Regarding BMY (NYSE:BMY), we observe a put option trade with bullish sentiment. It expires in 112 day(s) on September 20, 2024. Parties traded 64 contract(s) at a $47.00 strike. The total cost received by the writing party (or parties) was $42.8K, with a price of $670.0 per contract. There were 3098 open contracts at this strike prior to today, and today 211 contract(s) were bought and sold.

    • For UNH (NYSE:UNH), we notice a call option trade that happens to be bullish, expiring in 49 day(s) on July 19, 2024. This event was a transfer of 112 contract(s) at a $530.00 strike. The total cost received by the writing party (or parties) was $66.6K, with a price of $595.0 per contract. There were 786 open contracts at this strike prior to today, and today 161 contract(s) were bought and sold.

    • For DXCM (NASDAQ:DXCM), we notice a put option sweep that happens to be bearish, expiring in 168 day(s) on November 15, 2024. This event was a transfer of 127 contract(s) at a $110.00 strike. This particular put needed to be split into 32 different trades to become filled. The total cost received by the writing party (or parties) was $92.7K, with a price of $730.0 per contract. There were 346 open contracts at this strike prior to today, and today 141 contract(s) were bought and sold.

    • Regarding SRPT (NASDAQ:SRPT), we observe a call option sweep with bearish sentiment. It expires in 21 day(s) on June 21, 2024. Parties traded 91 contract(s) at a $160.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $46.4K, with a price of $510.0 per contract. There were 1044 open contracts at this strike prior to today, and today 117 contract(s) were bought and sold.

    • For ABBV (NYSE:ABBV), we notice a call option sweep that happens to be bearish, expiring in 385 day(s) on June 20, 2025. This event was a transfer of 151 contract(s) at a $180.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $89.1K, with a price of $590.0 per contract. There were 533 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold.

    • Regarding CVS (NYSE:CVS), we observe a call option sweep with bullish sentiment. It expires in 595 day(s) on January 16, 2026. Parties traded 50 contract(s) at a $67.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $550.0 per contract. There were 311 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $BMY
    $CVS
    $DHR

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    2/20/2026$75.00Overweight
    Barclays
    AbbVie Inc.
    $ABBV
    2/20/2026$275.00Overweight
    Barclays
    Praxis Precision Medicines Inc.
    $PRAX
    2/2/2026$282.00Equal Weight
    Wells Fargo
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    DexCom Inc.
    $DXCM
    1/12/2026$71.00Equal Weight → Underweight
    Barclays
    Exelixis Inc.
    $EXEL
    1/8/2026$48.00Overweight → Equal-Weight
    Morgan Stanley
    AbbVie Inc.
    $ABBV
    1/8/2026Outperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $ABBV
    $BMY
    $CVS
    $DHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Research and Development Aftab Dana sold $1,324,868 worth of shares (29,873 units at $44.35), decreasing direct ownership by 4% to 664,024 units (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    2/23/26 6:50:03 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Wyszomierski Jack L exercised 20,634 shares at a strike of $19.77 and sold $4,382,252 worth of shares (99,574 units at $44.01), decreasing direct ownership by 22% to 279,942 units (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    2/20/26 8:36:32 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, R&D and CSO Thakkar Roopal was granted 18,137 shares, increasing direct ownership by 43% to 60,413 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    2/20/26 6:36:48 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $CVS
    $DHR
    SEC Filings

    View All

    SEC Form S-8 filed by Moderna Inc.

    S-8 - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:03:07 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Moderna Inc.

    10-K - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:02:04 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by AbbVie Inc.

    10-K - AbbVie Inc. (0001551152) (Filer)

    2/20/26 2:38:42 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $CVS
    $DHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

    Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026. The company will take part in a fireside chat beginning at 9:50 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for

    2/23/26 4:16:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

    Investment marks continued progress against AbbVie's $100 billion commitment to U.S. research and development (R&D) and capital investments, including manufacturing, over the next decadeTwo new facilities will be built to add advanced manufacturing capabilities to support the production of next-generation neuroscience and obesity medicinesConstruction will begin in spring 2026, with the site fully operational in 2029NORTH CHICAGO, Ill., Feb. 23, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art faciliti

    2/23/26 11:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $CVS
    $DHR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $CVS
    $DHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Bristol-Myers with a new price target

    Barclays initiated coverage of Bristol-Myers with a rating of Overweight and set a new price target of $75.00

    2/20/26 8:24:06 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on AbbVie with a new price target

    Barclays initiated coverage of AbbVie with a rating of Overweight and set a new price target of $275.00

    2/20/26 8:23:14 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Praxis Precision Medicines with a new price target

    Wells Fargo initiated coverage of Praxis Precision Medicines with a rating of Equal Weight and set a new price target of $282.00

    2/2/26 6:51:57 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $CVS
    $DHR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Johnson David Edward bought $1,187,235 worth of shares (27,532 units at $43.12) (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    11/26/25 4:05:28 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $ABBV
    $BMY
    $CVS
    $DHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 7:53:30 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:50:15 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:46:12 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $CVS
    $DHR
    Leadership Updates

    Live Leadership Updates

    View All

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t

    1/13/26 4:30:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $BMY
    $CVS
    $DHR
    Financials

    Live finance-specific insights

    View All

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of

    2/19/26 9:37:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: Revenue grew 13% year-over-year to $1.260 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 18% on a reported basis and 15% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $323.0 million or 25.6% of revenue, an increase of 860 basis points compared to the fourth quarter of 2024. Non-GAAP operating income* of $331.5 million or 26.3% of reported revenue, an increase of 750 basis points compared to the fourth

    2/12/26 4:03:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care